Patents Assigned to Wyeth
  • Anti-5T4 antibodies and uses thereof
    Patent number: 8759495
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: June 24, 2014
    Assignee: Wyeth LLC
    Inventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
  • ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE
    Publication number: 20140171384
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: January 30, 2014
    Publication date: June 19, 2014
    Applicant: WYETH
    Inventors: Charles Michael ZACHARCHUK, Susan Elizabeth QUINN, Kenneth Kuan-Yuen WANG, Florence Marie Helene BINLICH
  • Triazine compounds as P13 kinase and MTOR inhibitors
    Patent number: 8748421
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: June 10, 2014
    Assignee: Wyeth LLC
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • Calicheamicin derivative-carrier conjugates
    Patent number: 8747857
    Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: June 10, 2014
    Assignee: Wyeth Holdings LLC
    Inventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
  • Pharmaceutical Suspension Composition
    Publication number: 20140142187
    Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Wyeth LLC
    Inventors: Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Alley
  • PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20140142132
    Abstract: The present invention provides a compound of formula I: wherein R1, R2, R2? and X? are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.
    Type: Application
    Filed: September 4, 2013
    Publication date: May 22, 2014
    Applicants: WYETH, LLC, PROGENICS PHARMACEUTICALS, INC.
    Inventors: Alfred A. Avey, Appavu Chandrasekaren, Harold D. Doshan, Julio Perez, Yakov Rotshteyn
  • CCI-779 formulations for parenteral administration
    Patent number: 8722700
    Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 13, 2014
    Assignee: Wyeth LLC
    Inventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
  • Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity
    Patent number: 8710202
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: April 29, 2014
    Assignee: Wyeth LLC
    Inventors: Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein, William J. Dunham
  • Modified and stabilized GDF propeptides and uses thereof
    Patent number: 8710025
    Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 29, 2014
    Assignee: Wyeth LLC
    Inventors: Neil M. Wolfman, Soo-Peang Khor, Kathleen N. Tomkinson
  • HIGH-CELL DENSITY FED-BATCH FERMENTATION PROCESS FOR PRODUCING RECOMBINANT PROTEIN
    Publication number: 20140113329
    Abstract: Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and optionally continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions and compositions for use in the methods of the present invention, are provided.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 24, 2014
    Applicant: Wyeth LLC
    Inventors: Wei-Qiang Willie Sun, Earl Joseph Pursell
  • Antineoplastic Combinations Containing HKI-272 and Vinorelbine
    Publication number: 20140107147
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 17, 2014
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Cyclic Progestin Regimens and Kits
    Publication number: 20140094458
    Abstract: A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.
    Type: Application
    Filed: November 8, 2013
    Publication date: April 3, 2014
    Applicant: Wyeth LLC
    Inventors: Gary Sondermann Grubb, Ginger Dale Constantine
  • PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES
    Publication number: 20140081010
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 20, 2014
    Applicant: WYETH LLC
    Inventors: Justin Keith MORAN, Jianxin GU
  • ANTIBODY-DRUG CONJUGATES
    Publication number: 20140081005
    Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: October 14, 2013
    Publication date: March 20, 2014
    Applicant: WYETH LLC
    Inventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova
  • PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20140080854
    Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 20, 2014
    Applicant: Wyeth
    Inventor: Wyeth
  • Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
    Patent number: 8669273
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 11, 2014
    Assignee: Wyeth LLC
    Inventors: Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
  • Tanaproget compositions containing ethinyl estradiol
    Patent number: 8664208
    Abstract: Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: March 4, 2014
    Assignee: Wyeth LLC
    Inventors: Arwinder Nagi, Ramarao Chatlapalli, Shamim Hasan, Zafar Ali, Mohamed Ghorab
  • Child resistant bulk dose dispensing unit
    Patent number: 8657136
    Abstract: Child-resistant bulk dose dispensing packaging unit, and a method for opening the packaging unit, including a container and a lid engaged with the container. The container includes a reservoir, an aperture at a top end of the reservoir, and a protrusion extending from a surface of the container. The lid engages with the container and slides between a closed position and an open position. The lid includes a top wall, a side wall extending down from an outer edge of the top wall, and a post configured to engage the protrusion at a first position when the lid is closed so as to keep the lid closed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: February 25, 2014
    Assignee: Wyeth LLC
    Inventors: Ari Tao Adler, Robert John McCaffrey
  • Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20140050721
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: April 30, 2013
    Publication date: February 20, 2014
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Shortened purification process for the production of capsular polysaccharides
    Patent number: 8652480
    Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: February 18, 2014
    Assignee: Wyeth LLC
    Inventors: Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela Fink